Stem Cell Therapy For Wound Healing Market Size, Share, Opportunities, And Trends By Type (Mesenchymal Stem Cells (Mscs), Adipose-Derived Stem Cells, Bone Marrow-Derived Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells (Ipscs), Other Stem Cell Types), By Application (Chronic Wounds, Acute Wounds, Surgical Wounds, Traumatic Wounds, Diabetic Foot Ulcers, Pressure Ulcers, Others), By Wound Type (Diabetic Ulcers, Venous Ulcers, Pressure Ulcers, Surgical Wounds, Traumatic Wounds, Others), By End-User (Hospitals And Clinics, Ambulatory Surgical Centers, Wound Care Centers, Research Institutions, Others), And By Geography - Forecasts From 2023 To 2028

  • Published : Oct 2023
  • Report Code : KSI061615990
  • Pages : 147

The stem cell therapy for wound healing market was valued at US$25.027 billion in 2021.

The stem cell therapy for wound healing market offers a transformational area in medical research, offering innovative approaches to difficult and non-healing wounds. Stem cell treatment uses stem cells' regenerative capacity to expedite wound healing processes. These treatments have promise for chronic wounds, diabetic ulcers, and severe burns, which frequently reject standard therapy. This market seeks to improve tissue regeneration, stimulate angiogenesis, and control inflammation by providing stem cells or their derivatives to injured tissues. As the frequency of chronic wounds develops in tandem with ageing populations and diabetes, stem cell therapy appears to be a potential treatment option. With continued advances in stem cell research, this market has the potential to transform wound care, promoting enhanced healing results and improving patient quality of life.

Rising Cases of Diabetic Ulcers and Non-Healing Wounds in the Stem Cell Therapy for Wound Healing Market.

The inclusion of digital tools, software, and devices to improve medical procedures, patient care, and health management is referred to as technology integration in healthcare solutions. Electronic health records (EHRs), telemedicine, wearable devices, mobile apps, and AI-driven analytics are all part of this. Technology promotes accessibility, efficiency, and accuracy in healthcare delivery by digitising medical information, enabling remote consultations, and providing real-time health monitoring. Personalised treatment, prompt interventions, and improved communication with healthcare providers benefit patients. Furthermore, technology-driven solutions simplify administrative processes, data exchange, and decision-making for healthcare practitioners, resulting in more effective, patient-centred, and data-driven healthcare practises.

Expanding Knowledge of Stem Cell Behaviour and Regeneration Enhances the Stem Cell Therapy for Wound Healing Market Growth.

By introducing game-like aspects to healthcare environments, gamification acts as a catalyst for encouraging excellent health behaviours. Individuals are encouraged to develop healthy behaviours and make educated decisions by using incentives, challenges, and interactive experiences. This method appeals to human psychology, eliciting intrinsic desire and engagement. Gamification improves regular exercise, medication adherence, balanced eating, and proactive disease management by converting health-related tasks into pleasurable and rewarding experiences. It fosters a sense of accomplishment, social connection, and progress monitoring, which reinforces desired behaviours. Finally, gamification uses behavioural psychology to empower people to take care of their health, resulting in long-term changes in lifestyle choices and general well-being.

Positive Outcomes from Studies Validating Stem Cell Therapies in the  Stem Cell Therapy for Wound Healing Market.

Gamified solutions can help patients manage chronic diseases by providing interesting and helpful platforms. These programmes make use of game-like aspects to improve adherence to treatment regimens, medication schedules, and lifestyle changes. Gamification encourages self-management and enables individuals to better understand and control their conditions by giving interactive challenges, progress monitoring, and personalised feedback. These systems also make data collecting easier, allowing healthcare personnel to remotely monitor patients and intervene as required. Gamified solutions efficiently aid individuals in managing chronic diseases by creating constant engagement, knowledge, and motivation, resulting in improved health outcomes and quality of life.

Europe is the Market Leader in the Stem Cell Therapy for Wound Healing Market.

Given its rich healthcare infrastructure, substantial research capabilities, and supportive regulatory environment, Europe is a market leader in the stem cell therapy for wound healing market. European nations have led the way in stem cell research and regenerative medicine, creating a favourable environment for developments in wound healing therapy. The ageing population of the region, as well as the increased occurrence of chronic wounds, fuel the desire for novel therapies. Collaborations between academic institutions, healthcare providers, and industry participants also help to accelerate advancement in this sector. Europe's concentration on patient safety and regulatory compliance places it at the forefront of researching and implementing stem cell-based treatments for wound healing, consolidating its position as the market leader in this revolutionary market.

Industry-Academic Collaborations to Accelerate Advancements Bolsters the Stem Cell Therapy for Wound Healing Market Size.

Collaborations between industry and academia are critical to advancing breakthroughs in the stem cell therapy for wound healing market. These collaborations combine the expertise of research institutions and industry participants, integrating intellectual ideas with practical development and commercialization initiatives. Collaborations accelerate research, preclinical studies, and clinical trials by facilitating the interchange of information, resources, and technology. Collaboration improves the translation of scientific findings into novel therapeutics, shortening development delays and promoting more efficient regulatory approvals. Collaborations of this type bridge the gap between academic discoveries and real-world applications, resulting in speedier advancement and better patient results. The collaboration of academia and business is critical to the rapid advancement of stem cell-based wound healing therapies.

Key Developments:

  • In January 2023, MiMedx Group, Inc., a pioneer and leader in placental biologics, announced that it has entered into an exclusive distribution deal for EPIFIX in Japan with GUNZE MEDICAL LIMITED, a subsidiary of Gunze Limited. Gunze Medical is a significant distributor of wound and surgical goods, including bioabsorbable devices and materials such as sutures and sheet products. The firm has over 90 sales agents and clinical support workers around the country, as well as excellent physician ties. MIMEDX and the Gunze Medical team will work together to expand physician education efforts and key opinion leader ("KOL") participation across the country.
  • In March 2023, Mölnlycke and ENGIE have signed a 15-year low-carbon energy and services cooperation to support our new mid- and long-term WeCare strategy, which includes greenhouse gas (GHG) emission reduction targets.
  • In December 2022, Integra LifeSciences Holdings Corporation, a global leader in medical technology, announced the completion of its purchase of Surgical Innovation Associates (SIA). 

Company Products:

  • Wound Care Products: Integra Lifesciences provides wound care solutions that enhance healing and tissue regeneration. Advanced dressings, skin replacements, and regenerative solutions are examples of these items.
  • Amniotic Tissue Products: MiMedx Group specialises in the development of amniotic tissue-based products generated from healthy donors' placental tissues. These items are intended to deliver growth factors, cytokines, and extracellular matrix components to aid in wound healing and tissue regeneration.
  • MACI® (autologous cultured chondrocytes on porcine collagen membrane): MACI is a cell therapy product created by Vericel that involves the collection and culture of a patient's own cartilage cells. It is primarily used for cartilage repair. While it is primarily used to repair cartilage, it demonstrates Vericel's competence in cell-based therapeutics.
  • Apligraf®: Apligraf is a living-cell therapy that has been bioengineered for the treatment of chronic wounds such as diabetic foot ulcers and venous leg ulcers. It is made up of keratinocytes and fibroblasts produced from newborn foreskin cells, as well as bovine collagen. 

Key Segment:

  • By Type
    • Mesenchymal Stem Cells (Mscs)
    • Adipose-Derived Stem Cells
    • Bone Marrow-Derived Stem Cells
    • Embryonic Stem Cells
    • Induced Pluripotent Stem Cells (Ipscs)
    • Other Stem Cell Types
  • By Application
    • Chronic Wounds
    • Acute Wounds
    • Surgical Wounds
    • Traumatic Wounds
    • Diabetic Foot Ulcers
    • Pressure Ulcers
    • Others 
  • By Wound Type
    • Diabetic Ulcers
    • Venous Ulcers
    • Pressure Ulcers
    • Surgical Wounds
    • Traumatic Wounds
    • Others
  • By End-User
    • Hospitals And Clinics
    • Ambulatory Surgical Centers
    • Wound Care Centers
    • Research Institutions
    • Others  
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain   
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Sources

2.3. Research Design


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Mesenchymal Stem Cells (MSCs)

5.3. Adipose-Derived Stem Cells

5.4. Bone Marrow-Derived Stem Cells

5.5. Embryonic Stem Cells

5.6. Induced Pluripotent Stem Cells (iPSCs)

5.7. Other Stem Cell Types                            


6.1. Introduction

6.2. Chronic Wounds

6.3. Acute Wounds

6.4. Surgical Wounds

6.5. Traumatic Wounds

6.6. Diabetic Foot Ulcers

6.7. Pressure Ulcers

6.8. Others                        


7.1. Introduction

7.2. Diabetic Ulcers

7.3. Venous Ulcers

7.4. Pressure Ulcers

7.5. Surgical Wounds

7.6. Traumatic Wounds

7.7. Others                                             


8.1. Introduction

8.2. Hospitals and Clinics

8.3. Ambulatory Surgical Centers

8.4. Wound Care Centers

8.5. Research Institutions

8.6. Others     


9.1. Introduction

9.2. North America

9.2.1. United States

9.2.2. Canada

9.2.3. Mexico

9.3. South America

9.3.1. Brazil

9.3.2. Argentina

9.3.3. Others

9.4. Europe

9.4.1. United Kingdom

9.4.2. Germany

9.4.3. France

9.4.4. Italy

9.4.5. Spain 

9.4.6. Others

9.5. Middle East and Africa

9.5.1. Saudi Arabia

9.5.2. UAE

9.5.3. Others

9.6. Asia Pacific

9.6.1. Japan

9.6.2. China

9.6.3. India

9.6.4. South Korea

9.6.5. Indonesia 

9.6.6. Taiwan

9.6.7. Others


10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix


11.1. Organogenesis Holdings Inc.

11.2. Osiris Therapeutics, Inc. (Now part of Smith & Nephew)

11.3. Vericel Corporation

11.4. Acelity L.P. Inc. (Acquired by 3M)

11.5. Mesoblast Limited

11.6. MiMedx Group, Inc.

11.7. Cytori Therapeutics, Inc.

11.8. Tissue Regenix Group plc

11.9. Athersys, Inc.

11.10. Anterogen Co., Ltd.             

Organogenesis Holdings Inc.

Osiris Therapeutics, Inc. (Now Part Of Smith & Nephew)

Vericel Corporation

Acelity L.P. Inc. (Acquired By 3m)

Mesoblast Limited

Mimedx Group, Inc.

Cytori Therapeutics, Inc.

Tissue Regenix Group Plc

Athersys, Inc.

Anterogen Co., Ltd.